FDA Approves MESALAMINE — KLM Laboratories Private Limited

# FDA Approves KLM Laboratories' Generic Mesalamine Rectal Formulation KLM Laboratories Private Limited received FDA approval for its generic mesalamine rectal formulation (ANDA220016), expanding treatment options for inflammatory bowel disease patients and intensifying competition in the rectal mesalamine market. The approval is expected to increase price competition and improve patient access to this established gastrointestinal therapeutic, potentially benefiting both payers and manufacturers with existing market share.